Paypal Confirms The E-commerce Rise

Paypal Confirms E-commerce Rise

More than three-quarters of S&P 500 companies have reported in this earnings season. Due to the COVID-19 crisis, it is rare to find companies delivering positive outlook for the upcoming quarters. Technology and healthcare are among the few industries that have reported positive surprises on average.

Yesterday, several of our top holdings released encouraging messages about their future activities given the current situation – e.g. Twilio (AI & Robotics portfolio) or Fortinet (Security & Space portfolio). In this note, we would like to comment on another company that benefits from the COVID-19, PayPal. The company is one of the top convictions of our Mobile Payments portfolio and a component of our Fintech portfolio.

PayPal has achieved a top-line CAGR of 18% over the last three calendar years. The company was on track to pursue its steady pace at the beginning of the year, with Total Payment Volume (TPV) increasing by 24% in January and 28% in February. The coronavirus outbreak initially decelerated revenue growth as TPV rose by “only” 8% in March. A slowdown in travel and events spending are the major reasons for this slowdown.

PayPal processed $191bn of volume over the first quarter of the year. Growth bounced back in April, reaching again 22% and implying a YoY revenue growth of 17%. The firm is expecting a YoY revenue growth of 15% for Q2-2020. Should be noted is that PayPal experienced the largest single day of transactions in the company’s history on 1 May 2020 – more than Black Friday or Cyber Monday 2019.

The number of new users matched the growth in revenue. In April 2020, a staggering number of 7.4mn subscribers joined the payment service. Knowing that in a typical quarter approximately 9.5mn new users join the PayPal service, the April numbers speak for themselves.

PayPal has now more than 330mn active accounts and pursue its 1 billion users global goal by primarily expanding outside the U.S. In addition to its strong network of merchants and consumers, the company is driving growth from partnerships with e-commerce platforms, banks, and payment networks.

The good results of the company confirm our thesis that COVID-19 is accelerating ecommerce adoption. E-commerce accounts for approximately 20% of total retail sales, where there is still a lot of room to grow.

Online consumption habits have been modified by the coronavirus, with a surge in food, fashion, gaming, or home & garden products. According to Emersys, online sales of US retailers doubled in April compared to 2019. In APAC, where the control measures started to be eased, e-commerce activities surged by more than 50% compared to 2019.

In a world where social distancing is becoming the norm, we strongly believe that ecommerce will continue its growth. People are modifying their consumption and payment habits. Our mobile payments and Fintech portfolios are well positioned to capture this trend.


Bottom line:

We believe that the Chinese biopharma sector is entering an important innovation cycle, thanks to supportive government reforms. The China FDA (CFDA) removed many clinical trial requirements and introduced a priority review designation to speed approvals. As a result, many Chinese and USA innovative drugs were approved, including Keytruda by Merck (MRK US), Repatha by Amgen (AMGNUS), or Spinraza by Biogen (BIIB US).

China also has a very competitive advantage: the sector can rely on important big data and its AI capabilities to stimulate fast-growing areas such as genomics and AI applications in healthcare.

In our biotechnology certificate, we currently have a direct exposure to the Chinese biopharma sector, albeit limited.

We are closely following the sector and may add more Chinese biopharma companies in the future.

Sources:

China Internet Network Information Center (CNNIC)
https://www.yicaiglobal.co  m/news/china-aims-usd146-billion-big-data-market-2020
Frost & Sullivan
Evaluate Pharma
Grandviewresearch.com
GLOBOCAN 2012: Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012, WHO, June 2017
https://www.scmp.com/sites/default/files/2014/05/30/5e8ef3511defc2f9b7963c0d172d047.jpg

Explore:



Disclaimer

This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.

As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.

The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.

Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.

It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.

Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.


Contact